Biotech cancer fighter Dendreon
Investors were right to cheer today: Provenge, a University of Washington doctor said in Dendreon's press release, "has the potential to change the way we treat prostate cancer in the future." Though a range of treatments is available, according to the National Prostate Cancer Coalition, there is also an ample supply of patients: Some 220,000 new cases are diagnosed each year. The disease is the most common cancer among American men.
David Nierengarten discussed Dendreon in September, looking also at Geron
Phase III trials are the big ones for any company that wants to sell a drug in the U.S. (Our Five Steps of Drug Development feature is a handy reference on this topic.) It's the final and most involved stage of a lengthy human testing process, and looks to determine not only the effectiveness of the treatment but also its potential side effects over time. Provenge, today's news indicates, scores favorably on both counts.
Next up is Food and Drug Administration approval, after which a drug can hit the market. At that point Dendreon, should things go its way, might really stand to reward investors who, despite today's pop, have watched the stock seesaw (and just barely outpace the S&P 500) since the company went public in mid-2000.
More from The Motley Fool
No Holiday Reprieve for 2 of the Biggest Retail Train Wrecks
Most department store chains have posted surprisingly strong results for the 2017 holiday season. However, these perennial laggards couldn't capitalize on the uptick in consumer spending.
3 Stocks That Could Put Amazon's Returns to Shame
These three tickers could be better bets than Amazon for new investors right now.
Will This iPhone Supplier’s Terrific Run Continue in 2018?
Lumentum's growing momentum in 3D sensing could help it overcome the weakness in the telecom segment.